Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
M Doortje ReijmanAnja SchweizerAmy L H PetersonEric BruckertChristian StratzJoep C DefescheRobert A HegeleAlbert WiegmanPublished in: European journal of preventive cardiology (2022)
https://www.clinicaltrials.gov/. Unique identifier: NCT04659863 (ORION-13) and NCT04652726 (ORION-16).